Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990, SHE:002422) recorded a profit attributable to equity holders of 388 million yuan for the first half, compared with an attributable loss of 145.2 million yuan a year prior.
Earnings per share stood at 1.6639 yuan, whereas the company had posted a loss per share of 0.6371 yuan previously, according to a Monday Hong Kong bourse filing.
Revenue rose 2.9% to 978.3 million yuan from 950.4 million yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.